|
|
 |
|
Viewing report
|
|
|
|
Jakafi (ruxolitinib) Gains US FDA Approval to Become the First Drug Ever to be Approved for Myelofibrosis
GlobalData, Nov 2011, Pages: 7
Jakafi (ruxolitinib) Gains US FDA Approval to Become the First Drug Ever to be Approved for Myelofibrosis
Summary
GlobalData, the industry analysis specialist, has released its new report, “Jakafi (ruxolitinib) Gains US FDA Approval to Become the First Drug Ever to be Approved for Myelofibrosis”. The report is an essential source of information and analysis in the myelofibrosis therapeutics market following the approval of Jakafi (ruxolitinib) for myelofibrosis, the first Janus-Associated Kinase (JAK) inhibitor ever to be approved for any indication. The report provides a brief insight on the myelofibrosis disease and its epidemiology. More importantly, the report provides valuable insights on the significance of Jakafi’s approval and the market scenario after this development. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the significance of Jakafi’s approval for myelofibrosis. Its scope includes -
- Current therapy options for myelofibrosis.
- Janus-Associated Kinase (JAK) Inhibitors.
- Deals between companies involved in conducting clinical trials on JAK inhibitors.
- Clinical Trial results leading to Jakafi’s approval and its significance.
- Market scenario, including Clinical Trials being pursued by different companies in the myelofibrosis space using the JAK inhibitors.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Understand the current scenario in myelofibrosis research with regard to JAK inhibitors.
- Formulate effective business strategies after understanding the competitive landscape vis-à-vis JAK inhibitors.
- Organize your sales and marketing efforts by identifying how Jakafi caters to the unmet need present in the myelofibrosis therapeutics market.
- Take an informed decision and try to leverage the opportunity and make investment decisions related to Jakafi or Incyte/Novartis.
|
|
|
|
